| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 07.02.
| UCB-Astellas Collaborate | | 5 | Zacks |
| 07.02.
| Science Buddies and Astellas USA Foundation Announce Chemistry Contest to Inspire Young Female Scientists | | 15 | PR Newswire |
| CARMEL, Calif. and DEERFIELD, Ill., Feb. 7, 2012 /PRNewswire/ -- Today, Science Buddies and Astellas USA Foundation ("Foundation") announced initiation of the Science Buddies-Astellas Rosalind Franklin...
Mehr lesen zu:
Science Buddies and Astellas USA Foundation Announce Chemistry Contest to Inspire Young Female Scientists | |
| 02.02.
| Medivation/Astellas' MDV3100 Shines | | 3 | Zacks |
| 01.02.
| Medivation, Astellas announce positive results from Phase III prostate cancer trial | | 8 | Pharma Bus Review |
| 01.02.
| Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy | | 2 | Benzinga.com |
| 01.02.
| Medivation (MDVN) and Astellas Pharma Report Positive Results from Phase 3 AFFIRM Trial | | - | StreetInsider.com |
| 01.02.
| Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy / MDV3100 Prolonged Life by 4.8 Months Compared to Placebo and Met All Secondary Endpoints
Medivation | | 72 | MarketWire |
| SAN FRANCISCO, CA and TOKYO -- (Marketwire) -- 01/31/12 -- Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced positive results on all efficacy endpoints from the Phase...
Mehr lesen zu:
Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy / MDV3100 Prolonged Life by 4.8 Months Compared to Placebo and Met All Secondary Endpoints
Medivation | |
| 19.01.
| Astellas Pharma Europe Ltd. Appoints Mike Crooks to Head up its UK Operations | | 41 | PR Newswire |
| STAINES, England, January 19, 2012 /PRNewswire/ --
Astellas Pharma Europe Ltd. (APEL), the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies...
Mehr lesen zu:
Astellas Pharma Europe Ltd. Appoints Mike Crooks to Head up its UK Operations | |
| 18.01.
| Astellas und XenoPort geben japanische Zulassung von Regnite®-Tabletten gegen Restless-Legs-Syndrom bekannt | | 45 | Business Wire |
| XenoPort soll Meilensteinzahlung in Höhe von 10 Millionen US-Dollar
erhalten
Astellas Pharma Inc. (Tokio: 4503) und XenoPort, Inc. (NASDAQ: XNPT)
...
Mehr lesen zu:
Astellas und XenoPort geben japanische Zulassung von Regnite®-Tabletten gegen Restless-Legs-Syndrom bekannt | |
| 18.01.
| Astellas, XenoPort Regnite tablet secures Japanese approval | | - | Pharma Bus Review |
| 18.01.
| Astellas and XenoPort Announce Approval of Regnite® Tablets for Restless Legs Syndrome in Japan | | 66 | Business Wire |
| XenoPort to Receive $10 Million Milestone Payment
Astellas Pharma Inc. (Tokyo:4503) and XenoPort, Inc. (NASDAQ:XNPT)
announced today that Regnite®
...
Mehr lesen zu:
Astellas and XenoPort Announce Approval of Regnite® Tablets for Restless Legs Syndrome in Japan | |
| 06.01.
| Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV(R) (telavancin) for Injection | | 189 | MarketWire |
| TOKYO and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/06/12 -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Theravance, Inc. (NASDAQ: THRX) today announced that Astellas has exercised its right...
Mehr lesen zu:
Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV(R) (telavancin) for Injection | |
| 03.01.
| AVEO Pharma (AVEO), Astellas Tivozanib Shows Superiority Over Sorafenib; Will Submit for Marketing Approval in FY12 | | 15 | StreetInsider.com |
|
03.01.
| AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial | | 130 | Business Wire |
| TIVO-1 is the First Registration Trial to Compare an Investigational
Agent to an Approved VEGF Therapy in First-line RCC
AVEO Conference Call Today at 8:30...
Mehr lesen zu:
AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial | |
| 21.12.
| UPDATE 1-Zogenix, Astellas to end co-promotion for migraine injection | | 10 | Reuters.com |
| 21.12.
| Zogenix (ZGNX), Astellas Announce End Date of UMAVEL DosePro Co-Promotion | | 3 | StreetInsider.com |
| 13.12.
| Die Europäische Kommission erteilt Astellas Pharma Europe Ltd. Marktzulassung zur Verwendung von DIFICLIR? in der EU | | 174 | news aktuell |
| Staines, Vereinigtes- Königreich (ots/PRNewswire) - Astellas Pharma Europe Ltd., eine europäische Tochtergesellschaft der in Tokio ansässigen Astellas Pharma Inc. (Tokio: 4503) und Optimer Pharmaceuticals...
Mehr lesen zu:
Die Europäische Kommission erteilt Astellas Pharma Europe Ltd. Marktzulassung zur Verwendung von DIFICLIR? in der EU | |
| 13.12.
| Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society | | 22 | PR Newswire |
| SAN DIEGO, Dec. 13, 2011 /PRNewswire/ --Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation announced today that updated results from an interim analysis...
Mehr lesen zu:
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society | |
| 12.12.
| Optimer (OPTR), Astellas Get EC MA for DIFICLIR Tabs as CDI Treatment | | 4 | StreetInsider.com |
| 01.12.
| Astellas Adds Two Key Senior Executives at Agensys, Inc. | | 31 | PR Newswire |
| SANTA MONICA, Calif., Dec. 1, 2011 /PRNewswire/ --Agensys, Inc. ("Agensys"), a subsidiary of Astellas (Tokyo:4503,"Astellas") has announced that Frank P. Hudson has been...
Mehr lesen zu:
Astellas Adds Two Key Senior Executives at Agensys, Inc. | |
